ProCE Banner Series

Looking to the Horizon: Emerging Therapies and the Near Future Evolution in Prostate Cancer

Join us live in San Francisco or online for an expert-led satellite symposium and simulcast focused on emerging therapies for prostate cancer. Experts will discuss the latest evidence, answer audience questions, discuss unanswered questions, and highlight key clinical trials being presented at ASCO GU. Register now!

Clinical Care Options, LLC is committed to providing a safe and healthy environment for all our learners. Our decisions and preventive measures are guided by the requirements and recommendations of the CDC alongside federal, state, and local health authorities. We work with each program venue to implement preventive measures to reduce the potential spread of COVID-19. In addition, ASCO will refer to the CDC COVID-19 Community Levels (Low, Medium, High) and associated Prevention Actions to guide health precautions for in-person meetings.

For more information on ASCO’s vaccination and mask requirements, please visit: ASCO’s website

Not an official event of the 2023 ASCO Genitourinary Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation.

  AMA
  | AMA
Credits Available

1.5

Who Should Attend

This educational program is intended for medical oncologists, urologists, and other healthcare professionals who treat patients with prostate cancer.

Faculty

ProCE Banner Faculty
Neeraj Agarwal, MD

Professor of Medicine
Senior Director for Clinical Research, Huntsman Cancer Institute (HCI)
Presidential Endowed Chair of Cancer Research
Director, Center of Investigational Therapeutics
Director, Genitourinary Oncology Program
Huntsman Cancer Institute, University of Utah (NCI-CCC)
Salt Lake City, Utah

ProCE Banner Faculty
Tanya B. Dorff, MD

Professor of Medicine
Vice Chair for Clinical Affairs
Department of Medical Oncology
City of Hope National Medical Center
Duarte, California

ProCE Banner Faculty
Rana R. McKay, MD

Associate Professor
Department of Medicine
Divisions of Hematology/Oncology and Urology
University of California San Diego
San Diego, California

Topics

Looking to the Horizon: Emerging Therapies and the Near Future Evolution in Prostate Cancer

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact meetings@clinicaloptions.com prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in the integration of novel therapies into the care of patients with prostate cancer. 

Target Audience
This educational program is intended for medical oncologists, urologists, and other healthcare professionals who treat patients with prostate cancer. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Appraise novel therapeutically actionable molecular targets that hold promise as predictive or prognostic biomarkers for patients with prostate cancer
  • Plan optimal, individualized sequential therapeutic strategies for prostate cancer, considering all available agents, clinical data including novel investigational therapeutics and imaging techniques, and expert recommendations
  • Identify patients with prostate cancer who may be eligible for enrollment on ongoing clinical studies investigating novel regimens 
  • Assess recent trial evidence from studies that evaluated novel approaches for prostate cancer in the context of their impact on evolving paradigms in the field

Accreditation

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO) and ProCE, LLC. Clinical Care
Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by educational grants from Exelixis, Inc., Lilly, and Pfizer, Inc.